Ionis widens eplontersen agreement with AstraZeneca; Inozyme looks to get $60M in public offering
AstraZeneca is paying $20 million to Ionis to gain commercialization rights in Latin America for a drug waiting for the FDA’s signoff.
Ionis said Friday morning that it expanded its collaboration with the UK pharma for eplontersen, an antisense drug that is being tested for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a neurodegenerative disease.
In 2021 AstraZeneca gave Ionis $200 million upfront with the potential for up to $485 million in development milestones and up to $2.9 billion in sales milestones. The deal gave the drugmaker the rights to the drug outside the US, excluding certain countries in Latin America.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.